Researchers in Istanbul gave a single oral dose of the mTOR inhibitor everolimus to male mice at three ages and tracked how much drug reached the bloodstream and liver over 24 hours. Older mice absorbed markedly less drug. Systemic exposure fell by more than half from youth to old age, while the rate at which the body cleared the drug roughly tripled. The surprising part is the mechanism. The decline was not driven by the liver enzymes that usually break down such drugs, but by a gut gatekeeper protein called P-glycoprotein that pumps the drug back out of the intestine before it can be absorbed. The authors argue that dosing the same milligrams-per-kilogram at every age is a mistake, and that blood-level monitoring should guide dosing in older patients.
The big idea here is deceptively simple and often ignored: the dose is not the drug. What matters biologically is how much of a drug actually gets into the body and stays there, and that quantity can change dramatically with age even when the pill on the plate is identical.
To test this, the team dosed male C57BL/6J mice at three life stages, roughly nine weeks, twenty-three weeks, and fifty-six weeks, with a single oral dose of everolimus. They then drew blood across a full day and measured drug levels, repeating the exercise in liver tissue. The pattern was consistent and sizeable. Total drug exposure in the blood was more than double in young animals compared with old ones. Peak blood concentration was about ninety-five percent higher in the young. Meanwhile the body’s apparent clearance of the drug more than tripled with age, and the volume into which the drug distributed more than doubled, consistent with older animals carrying more body fat for this fat-loving molecule to hide in.
The mechanistic twist is what lifts this above a routine dosing study. Everyone expected the liver to be the culprit, since the cytochrome enzyme that metabolizes everolimus, Cyp3a, is known to fall with age. It did fall here, by more than half at the gene level. But liver protein levels of the enzyme barely moved, so the liver could not explain the drop in drug exposure. The real gatekeeper was in the gut. P-glycoprotein, an efflux pump that sits in the intestinal wall and spits drug molecules back into the gut before they can cross into the blood, rose roughly four-fold at the protein level in the intestines of older mice. More pump means less drug absorbed. The correlation between gut pump levels and blood exposure was strongly negative, pointing to intestinal efflux, not liver metabolism, as the dominant age-sensitive barrier.
The liver told a stranger, U-shaped story. Liver drug levels dropped from young to middle age, then rebounded in old animals, likely because aging liver tissue becomes fattier and more permeable, letting this lipophilic drug pool there even as blood levels fall. The practical message the authors draw is that fixed age-blind dosing is unreliable for this drug class, and that measuring actual blood levels beats guessing from age alone.
Actionable Insights
For anyone using rapalogs such as rapamycin or everolimus off-label for healthspan, the core lesson is that the same weekly milligram dose likely does not produce the same blood level as you age. In these mice, older animals reached less than half the systemic drug exposure of young animals from an identical dose. In plain terms of magnitude, the standardized effect size for that drop in exposure was very large by conventional benchmarks, on the order of two standard deviations of separation between young and old, which means the age groups barely overlapped. Even under a more conservative reading of the paper’s own variability, the effect remains at least moderate to large.
The practical takeaways are: First, age changes exposure, so if you or a clinician are titrating a rapalog, blood-level monitoring is far more informative than a fixed dose. Second, the bottleneck is your gut, not just your liver, so anything that alters intestinal P-glycoprotein could shift exposure. Third, It says older bodies may see less of it per dose.
Context and Source
- Open Access Paper: Impact of aging on the pharmacokinetic profile of everolimus in male mice.
- Authors: Dilek Ozturk Civelek, Ferdi Ozturk, Yasemin Kubra Akyel, and Alper Okyar.
- Institutions and country: Departments of Pharmacology at Bezmialem Vakif University and Istanbul University, with contributions from Istanbul Medipol University.
- Journal: BMC Pharmacology and Toxicology (Springer Nature / BMC).
- Impact evaluation: The most recent two-year Journal Impact Factor is approximately 2.9 (2023 JCR, with sources reporting values between about 2.9 and 3.5), and the CiteScore is approximately 4.2 therefore this is a Low impact journal on the general-science scale.